Conference Coverage

NSAIDs for spondyloarthritis may affect time to conception


 

AT ACR 2022

Control before conception is important

Sinead Maguire, MD, a clinical and research fellow in the Spondylitis Program at Toronto (Ont.) Western Hospital who was not part of the study, said the study highlights the importance of optimizing disease control before conception.

Dr. Sinead Maguire, a clinical and research fellow in the Spondylitis Program at Toronto (Ont.) Western Hospital

Dr. Sinead Maguire

“There are a number of things rheumatologists can do to support our SpA patients when they are trying to conceive,” she told this news organization. “One of the most important issues to address is ensuring their SpA is in remission and continues to remain so. For that reason, if a woman is requiring regular NSAIDs for symptom control, the results of this study might encourage me to consider a biologic agent sooner to ensure remission.”

She urged women who want to become pregnant to discuss medications with their rheumatologist before trying to conceive.

“It is very exciting to see studies such as this so that rheumatologists can provide answers to our patients’ questions with evidence-based advice,” she said.

Ms. Hamroun and several coauthors had no disclosures. Other coauthors disclosed relationships with companies including Merck/MSD, Novartis, Janssen, AbbVie/Abbott, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Galapagos, Eli Lilly, Novartis, and/or UCB. Dr. Maguire reports no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Spondyloarthritis disease activity measurement with ASDAS not influenced by gender
MDedge Rheumatology
Around 10% of back pain patients referred by chiropractors have undiagnosed SpA
MDedge Rheumatology
Hormones’ impact described in transgender rheumatology patients
MDedge Rheumatology
Sex differences seen in inflammatory arthritis health care use
MDedge Rheumatology
Breakthrough COVID studies lend support to use of new boosters in immunosuppressed patients
MDedge Rheumatology
Who are the patients with longstanding ankylosing spondylitis without syndesmophytes?
MDedge Rheumatology
FDA approves upadacitinib (Rinvoq) for sixth indication
MDedge Rheumatology
Two biologics equally effective for extraintestinal manifestations of IBD
MDedge Rheumatology
Therapeutic drug monitoring pays off for arthritis patients
MDedge Rheumatology
Retention rates high after biosimilar-to-biosimilar switch for inflammatory arthritis
MDedge Rheumatology